Clinical Trial Update: A Multi-Center Study of MYOBLOC for the Treatment of Sialorrhea in Parkinson's Disease Patients [Phase 2]

View source ↗

Summary

Phase 2 study evaluating MYOBLOC for treating sialorrhea in Parkinson's disease has completed, with results posted August 13, 2009.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• MYOBLOC (rimabotulinumtoxinB)

Snippet

Sponsor: Solstice Neurosciences, LLC, a subsidiary of US WorldMeds, LLC | Conditions: Drooling | Phase 2 | Status: COMPLETED | Results posted: 2009-08-13